Compare Incyte Corporation (INCY) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Oxford Lane Capital Corp — how do they compare? Incyte Corporation trades at $117.76 (market cap $23.11B), while Oxford Lane Capital Corp trades at $8.96 (market cap $866.15M). The key difference: Incyte Corporation is far larger — about 26.7× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 27.06% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | OXLC | |
|---|---|---|
Market Cap | $23.11B | $866.15M |
Sector | Health | Financials |
52-Week High | $118.52 | $19.90 |
52-Week Low | $67.38 | $8.15 |
Enterprise Value | $19.13B | — |
Dividend Yield | — | 27.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
OXLC trades at $8.87, up 1.14% today, but faces a bearish technical outlook with negative moving averages and oscillators. The stock shows mixed fundamentals with a low P/B of 0.83 but alarming profitability metrics including a -39.16% ROE and three consecutive quarterly EPS misses. Recent news highlights concerns over its 24% dividend yield sustainability and a sharp net asset value decline reported in May 2026.
The outlook is cautious due to deteriorating earnings, high dividend risks, and negative cash flow from operations. While the P/B ratio suggests potential undervaluation, significant headwinds from poor ROE, volatile revenue, and bearish analyst sentiment outweigh opportunities. Investors should prioritize risk management amid ongoing financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
